Bottles of Xanax – one of the most widely-prescribed medications for anxiety – have been recalled after failing a quality-control test, according to the Food and Drug Administration.
Viatris, Inc., a Pennsylvania-based pharmaceutical firm, in March initiated a voluntary recall of its 60-tablet bottles of Xanax, citing “failed dissolution specifications,” food safety regulators said.
That means a drug has failed a quality control test, implying the Xanax does not deliver the correct dosage over time and is not being properly absorbed.
Last week, the FDA classified it as a Class II recall, meaning use of the product may cause “temporary or medically reversible adverse health consequences.”
The recalled bottles of Xanax were distributed nationwide between Aug. 27, 2024, and May 29, 2025, according to the California State Board of Pharmacy.
Patients should check their bottles for lot #8177156 and an expiration date of Feb. 28, 2027, to see if their prescriptions are included in the recall.
The California State Board said the recall was made “out of an abundance of caution,” adding it is not aware of any reports of adverse reactions.
Xanax is a benzodiazepine, or sedative, often used to treat panic and anxiety disorders over a short-term basis.
Viatris did not immediately respond to noti.group’s request for comment.
[Notigroup Newsroom in collaboration with other media outlets, with information from the following sources]
